Page last updated: 2024-11-07

mitiglinide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mitiglinide is an oral hypoglycemic agent used in the treatment of type 2 diabetes. It acts by stimulating insulin secretion from pancreatic beta cells, primarily through a mechanism involving potassium channel blockade. Mitiglinide is a synthetic compound structurally related to the natural product gliclazide. Its synthesis involves a multi-step process starting from commercially available starting materials. Mitiglinide has been shown to improve glycemic control in patients with type 2 diabetes, resulting in lower blood glucose levels. It is particularly useful in patients who are not adequately controlled by diet and exercise alone or who are intolerant to other oral hypoglycemic agents. Mitiglinide is often used in combination with other antidiabetic drugs, such as metformin, to achieve better glycemic control. Extensive research has been conducted on mitiglinide to evaluate its efficacy, safety, and pharmacodynamic properties. Studies have investigated its impact on blood glucose levels, insulin secretion, and cardiovascular outcomes. The importance of mitigating research lies in its potential to contribute to the development of novel and effective treatments for type 2 diabetes, a growing public health concern globally. Further studies are ongoing to investigate its long-term safety and efficacy, as well as its potential role in combination therapy and in specific patient populations.'

mitiglinide: a rapid and short-acting hypoglycemic agent; acts on sulfonylurea receptor closing KATP channels; considered one of the glinides-an imprecise grouping; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121891
CHEMBL ID471498
CHEBI ID135349
SCHEMBL ID49085
MeSH IDM0350233

Synonyms (29)

Synonym
AC-632
145375-43-5
mitiglinide [inn]
mitiglinide
DB01252
CHEBI:135349
CHEMBL471498
(2s)-4-[(3ar,7as)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoic acid
(-)-(2s,3a,7a-cis)-alpha-benzylhexahydro-gamma-oxo-2-isoindolinebutyric acid
unii-d86i0xlb13
d86i0xlb13 ,
WPGGHFDDFPHPOB-BBWFWOEESA-N
(s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionic acid
SCHEMBL49085
(-)-(2s,3a,7a-cis)-a-benzylhexahydro-.gamma.-oxo-2-isoindolinebutyric acid
mitiglinide [who-dd]
mitiglinide [mart.]
mitiglinide [mi]
DTXSID4048303
AKOS025149480
[2(s)-cis]-octahydro-gamma-oxo-alpha-(phenylmethyl)-2h-isoindole-2-butanoic acid
(s)-2-benzyl-4-((3ar,7as)-1h-isoindol-2(3h,3ah,4h,5h,6h,7h,7ah)-yl)-4-oxobutanoic acid
Q266321
(2s)-4-[(3as,7ar)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoic acid
(s)-2-benzyl-4-((3ar,7as)-octahydro-2h-isoindol-2-yl)-4-oxobutanoic acid
(2s)-4-[(3ar,7as)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-4-oxidanylidene-2-(phenylmethyl)butanoic acid
9I0 ,
CS-0009585
HY-B0682

Research Excerpts

Overview

Mitiglinide is a rapid- and short-acting insulinotropic sulfonylurea receptor ligand. It features rapid hypoglycemic action.

ExcerptReferenceRelevance
"Mitiglinide (MTG) is a novel oral hypoglycemic drug. "( Chromatographic Separation of the Novel Hypoglycemic Drug Mitiglinide in its Bulk Powder and Pharmaceutical Formulation: Forced Degradation and Validated Stability-Indicating HPTLC/Densitometry and HPLC/UV Methods.
Darweish, E; Eissa, MS; Elghobashy, MR; Shehata, MA, 2020
)
2.25
"Mitiglinide is a widely used agent for diabetic treatment. "( Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers.
Chen, P; Dai, G; Ding, A; Ju, W; Liu, S; Sun, B; Wang, Y; Zhao, Y, 2017
)
2.15
"Mitiglinide is a new insulinotropic agent of the glinide class and its precise mechanism is not very clear yet. "( Effect of mitiglinide on Streptozotocin-induced experimental type 2 diabetic rats: a urinary metabonomics study based on ultra-performance liquid chromatography-tandem mass spectrometry.
Cai, S; Huo, T; Li, F; Lu, X; Xu, J; Zheng, S, 2009
)
2.2
"Mitiglinide is a rapid- and short-acting insulinotropic sulfonylurea receptor ligand and features rapid hypoglycemic action. "( Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis.
Abe, M; Maruyama, N; Maruyama, T; Matsumoto, K; Okada, K, 2010
)
2.11
"Mitiglinide (MGN) is a new insulinotropic agent of the glinide class with rapid onset. "( The effects of food on the pharmacokinetics of mitiglinide tablets in healthy volunteers and a novel mass-spectrometric (UPLC-MS/MS) method for such studies.
Cai, LJ; Peng, WX; Yang, J; Zhang, J; Zhang, QZ; Zhu, RH, 2012
)
2.08
"Mitiglinide is a short-acting insulinotropic agent used in type 2 diabetes treatment."( Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide.
Hashikata, T; Hatakeyama, Y; Kameda, R; Kitasato, L; Tojo, T; Yamaoka-Tojo, M, 2012
)
1.33
"Mitiglinide (MGN) is a new potassium channel antagonist for the treatment of type 2 diabetes mellitus. "( Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases.
Lin, Y; Lu, S; Yu, L; Zeng, S, 2007
)
2.08

Effects

Mitiglinide has been shown through small clinical studies (N <400) to modestly decrease hemoglobin A(1c), postprandial hyperglycemia, and oxidative stress and inflammatory markers.

ExcerptReferenceRelevance
"Mitiglinide has been shown through small clinical studies (N <400) to modestly decrease hemoglobin A(1c), postprandial hyperglycemia, and oxidative stress and inflammatory markers associated with postprandial hyperglycemia. "( Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus.
Phillippe, HM; Wargo, KA, 2010
)
3.25
"Mitiglinide has been recommended for approval in Japan for the management of postprandial hyperglycaemia in patients with type 2 diabetes."( Mitiglinide: KAD 1229, S 21403.
, 2004
)
2.49

Toxicity

ExcerptReferenceRelevance
" Subsequently, the doses were titrated by dose-doubling to a maximum of 30 mg/day if no adverse effects appeared."( Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis.
Abe, M; Maruyama, N; Maruyama, T; Matsumoto, K; Okada, K, 2010
)
0.67
" The prevalence of adverse events and the risk of hypoglycemia were similar for both groups."( A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes.
Baik, SH; Cha, BS; Jang, HC; Lee, IK; Lee, KW; Park, TS; Son, JW; Sung, YA; Woo, JT; Yoo, SJ; Yoon, KH, 2015
)
0.62

Pharmacokinetics

Microsponges of the novel short half-life mitiglinide calcium (MTG) were formulated using Quasi-emulsion solvent diffusion method, employing Eudragit RS100, ethyl cellulose, and polyvinyl alcohol. In vitro buoyancy, in vitro drug release, and in vitro pharmacokinetics were measured in rabbits.

ExcerptReferenceRelevance
" The validated method was successfully used to analyze human plasma samples for application in pharmacokinetic studies."( Liquid chromatography/electrospray ionization tandem mass spectrometry for the quantification of mitiglinide in human plasma: validation and its application to pharmacokinetic studies.
Ding, L; Tian, Y; Wen, A; Yang, J; Yang, L; Zhang, Y, 2008
)
0.56
" The effects of food intake on the pharmacokinetic (PK) profile of mitiglinide tablets after single oral administration have not yet been reported in healthy adults."( The effects of food on the pharmacokinetics of mitiglinide tablets in healthy volunteers and a novel mass-spectrometric (UPLC-MS/MS) method for such studies.
Cai, LJ; Peng, WX; Yang, J; Zhang, J; Zhang, QZ; Zhu, RH, 2012
)
0.87
" The method was successfully used to analyze rats plasma samples for application in pharmacokinetic studies."( Effect of gemfibrozil on the pharmacokinetics of mitiglinide in rats.
Cao, Q; Jin, L, 2012
)
0.63
" Administration of a FDC tablet and concomitant administration of individual formulations did not show significantly different pharmacokinetic profiles."( Pharmacokinetics of a fixed-dose combination of mitiglinide and metformin versus concurrent administration of individual formulations in healthy subjects: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover study.
Huh, W; Jung, JA; Kim, JR; Kim, SR; Kim, TE; Ko, JW; Lee, SY, 2012
)
0.63
" Thus, microsponges of the novel short half-life mitiglinide calcium (MTG) were formulated using Quasi-emulsion solvent diffusion method, employing Eudragit RS100, ethyl cellulose, and polyvinyl alcohol, then characterized in terms of production yield, entrapment efficiency, particle size, in vitro buoyancy, in vitro drug release, and in vivo pharmacokinetics in rabbits."( Gastroretentive Microsponge as a Promising Tool for Prolonging the Release of Mitiglinide Calcium in Type-2 Diabetes Mellitus: Optimization and Pharmacokinetics Study.
ElMeshad, AN; Mahmoud, DBED; Shukr, MH, 2018
)
0.96

Compound-Compound Interactions

Mitiglinide is novel class of rapid-acting insulin secretagogues, which have been widely used alone or in combination with other oral hypoglycemic drugs.

ExcerptReferenceRelevance
"Mitiglinide is novel class of rapid-acting insulin secretagogues, which have been widely used alone or in combination with other oral hypoglycemic drugs to improve postprandial hyperglycemia in early type 2 diabetes."( Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus.
Abe, M; Hara, K; Hirose, T; Kanazawa, A; Kanazawa, Y; Kanno, R; Kawai, J; Kawamori, R; Kumashiro, N; Mita, T; Miwa, S; Motojima, K; Sakai, K; Sakurai, Y; Sato, F; Shimizu, T; Tanaka, Y; Uchino, H; Watada, H; Yamazaki, Y; Yoshihara, T, 2006
)
2.08
" The urinary glucose excretion was drastically elevated in the dapagliflozin group, but the combination with mitiglinide suppressed it about 50%."( Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats.
Akahane, K; Inoue, T; Kiguchi, S; Kobayashi, M; Maruyama, K; Mori, Y; Ojima, K; Yaguchi, A; Yokoyama, A, 2015
)
1.01
"We compared the individual effects of mitiglinide and glibenclamide administered in combination with the dipeptidyl peptidase-IV (DPP-IV) inhibitor sitagliptin on plasma DPP-IV activity and blood glucose levels in rats with streptozotocin-nicotinamide-induced type 2 diabetes (STZ-NA rats)."( Comparison of the Effects of Mitiglinide and Glibenclamide Administered in Combination with the Dipeptidyl Peptidase-IV Inhibitor Sitagliptin in Rats with Streptozotocin-Nicotinamide-Induced Type 2 Diabetes.
Akahane, K; Inoue, T; Kiguchi, S; Kobayashi, M; Ojima, K; Takeda, H; Tatemichi, S; Yokoyama, A, 2017
)
1.02

Bioavailability

ExcerptReferenceRelevance
" Consequently, the bioavailability of mitiglinide in the presence of gemfibrozil was significantly enhanced compared to that in oral control group (only mitiglinide)."( Effect of gemfibrozil on the pharmacokinetics of mitiglinide in rats.
Cao, Q; Jin, L, 2012
)
0.9
" Thus, our goal was to assess the possibility of using cosolvency approach in formulating gastroretentive in situ gel of the short half-life MTG to simultaneously enhance its bioavailability and sustain its release."( Gastroretentive Cosolvent-Based In Situ Gel as a Promising Approach for Simultaneous Extended Delivery and Enhanced Bioavailability of Mitiglinide Calcium.
ElMeshad, AN; Mahmoud, DB; Shukr, MH, 2019
)
0.72

Dosage Studied

The results of our experiment suggested that the model can be used reasonably to predict the relationship between PK and PD in mitiglinide. The model could be used in diabetes mellitus dosage control in clinical trials and other fields.

ExcerptRelevanceReference
" Because of a more intensive dosing regimen, potential cost, and lack of studies assessing the clinical impact of mitiglinide therapy on oxidative stress and inflammatory markers secondary to postprandial hyperglycemia, we cannot recommend this therapy over currently approved therapies."( Mitiglinide: a novel agent for the treatment of type 2 diabetes mellitus.
Phillippe, HM; Wargo, KA, 2010
)
2.01
" At 13 weeks of age, ZF rats were dosed orally with dapagliflozin once daily up to the 22(nd) day."( Efficacy of Mitiglinide Combined with Dapagliflozin in Streptozotocin-nicotinamide-induced Type 2 Diabetic Rats and in Zucker Fatty Rats.
Akahane, K; Inoue, T; Kiguchi, S; Kobayashi, M; Maruyama, K; Mori, Y; Ojima, K; Yaguchi, A; Yokoyama, A, 2015
)
0.8
" The results of our experiment suggested that the model can be used reasonably to predict the relationship between PK and PD in mitiglinide, which could be used in diabetes mellitus dosage control in clinical trials and other fields."( Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers.
Chen, P; Dai, G; Ding, A; Ju, W; Liu, S; Sun, B; Wang, Y; Zhao, Y, 2017
)
0.91
" These formulations will improve diabetic patients' compliance by eliminating the necessity of frequent dosing with a better disease management."( Gastroretentive Cosolvent-Based In Situ Gel as a Promising Approach for Simultaneous Extended Delivery and Enhanced Bioavailability of Mitiglinide Calcium.
ElMeshad, AN; Mahmoud, DB; Shukr, MH, 2019
)
0.72
"Fixed-dose combination (FDC) medicines containing two or more active pharmaceutical ingredients (APIs) in a single dosage form have been reported to improve patient adherence to a greater extent than single dosages of individual components (ICs)."( Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets.
Hakamata, A; Inui, N; Kamiya, C; Kashiwagura, Y; Namiki, N; Odagiri, K; Sotoyama, M; Tanaka, S; Uchida, S; Watanabe, H, 2019
)
0.75
"The adopted methods were successfully applied for the determination of MTG in its pure form, in presence of its acid degradant and in its tablet dosage form."( Chromatographic Separation of the Novel Hypoglycemic Drug Mitiglinide in its Bulk Powder and Pharmaceutical Formulation: Forced Degradation and Validated Stability-Indicating HPTLC/Densitometry and HPLC/UV Methods.
Darweish, E; Eissa, MS; Elghobashy, MR; Shehata, MA, 2020
)
0.8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID364053Increase in insulin releasing activity in Syrian golden hamster HIT-T15 cells at 100 uM after 1 hr relative to control2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Insulin-releasing activity of a series of phenylalanine derivatives.
AID1744122Inhibition of human ACMSD assessed as picolinic acid level at 1 mM by HPLC analysis (Rvb = 83.6 +/- 3.1%)2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
AID364056Decrease in plasma glucose level in Sprague-Dawley rat at 3 mg/kg, po after 15 mins relative to control2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Insulin-releasing activity of a series of phenylalanine derivatives.
AID364051Increase in insulin releasing activity in Syrian golden hamster HIT-T15 cells at 1 uM after 1 hr relative to control2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Insulin-releasing activity of a series of phenylalanine derivatives.
AID364057Decrease in plasma glucose level in Sprague-Dawley rat at 3 mg/kg, po after 30 mins relative to control2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Insulin-releasing activity of a series of phenylalanine derivatives.
AID364052Increase in insulin releasing activity in Syrian golden hamster HIT-T15 cells at 10 uM after 1 hr relative to control2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Insulin-releasing activity of a series of phenylalanine derivatives.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID364059Decrease in plasma glucose level in Sprague-Dawley rat at 3 mg/kg, po after 120 mins relative to control2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Insulin-releasing activity of a series of phenylalanine derivatives.
AID364060Decrease in plasma glucose level in Sprague-Dawley rat at 3 mg/kg, po after 180 mins relative to control2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Insulin-releasing activity of a series of phenylalanine derivatives.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID364058Decrease in plasma glucose level in Sprague-Dawley rat at 3 mg/kg, po after 60 mins relative to control2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Insulin-releasing activity of a series of phenylalanine derivatives.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID364054Increase in insulin releasing activity in Syrian golden hamster HIT-T15 cells after 1 hr2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Insulin-releasing activity of a series of phenylalanine derivatives.
AID1744121Inhibition of human ACMSD assessed as QUIN level at 1 mM by HPLC analysis (Rvb = 16.4 +/- 2.9%)2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (116)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's23 (19.83)18.2507
2000's39 (33.62)29.6817
2010's50 (43.10)24.3611
2020's4 (3.45)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.34 (24.57)
Research Supply Index5.02 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index55.12 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials30 (25.00%)5.53%
Reviews18 (15.00%)6.00%
Case Studies2 (1.67%)4.05%
Observational0 (0.00%)0.25%
Other70 (58.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Rapid Onset and Short Duration Insulin Secretogogue, Mitiglinide, in Combination With Metformin Versus Metformin Alone in Patients With Type 2 Diabetes Mellitus: A Randomized, Double-blind, Placebo-controlled Trial for 6 Months [NCT00519142]Phase 3367 participants (Actual)Interventional2007-08-31Completed
An Open, Multi-center, Randomized Study to Evaluate the Efficacy and Safety of Mitiglinide Versus Acarbose in Patients With Type 2 Diabetes Mellitus in China [NCT02143765]Phase 4248 participants (Actual)Interventional2014-05-31Completed
Phase 3 Study of Combination of Mitiglinide and Metformin in Patients With Type 2 Diabetes Mellitus [NCT01037842]Phase 3145 participants (Actual)Interventional2006-08-31Completed
Pharmacokinetic Study of ASP1941 -A Pharmacokinetic Study to Assess Drug-Drug Interaction Between ASP1941 and Mitiglinide Calcium Hydrate [NCT01403818]Phase 160 participants (Actual)Interventional2011-06-30Completed
A Prospective, Randomized and Multi-center Clinical Study to Evaluate Efficacy and Safety of Combination Therapy of Mitiglinide or Voglibose With Long-acting Insulin in Type 2 Diabetic Patients [NCT00663884]Phase 4167 participants (Actual)Interventional2008-02-29Completed
Pharmacodynamics After Concomitant Administration With Mitiglinide and Sitagliptin Compared to Mitiglinide, Sitagliptin Single Administration in Patients With Type 2 Diabetes [NCT01422590]Phase 126 participants (Actual)Interventional2010-05-31Completed
Multicentre, Double-Dummy, Randomized, Double-Blind Comparison Between Mitiglinide and Nateglinide in the Patients With Type 2 Diabetes [NCT00461617]Phase 3291 participants (Actual)Interventional2006-08-31Completed
Evaluation of Usefulness of Combination Therapy of Rapid Acting Insulin Secretagogue (Glinide) With Premixed Insulin in Type 2 Diabetes [NCT00369148]Phase 460 participants Interventional2004-07-31Completed
A Multicenter, Open Label, Long-term Study of KAD-1229 in Type 2 Diabetes Patients Who Show Inadequate Glycemic Control With Diet, and Biguanide or DPP-4 Inhibitor Monotherapy [NCT01333592]Phase 3136 participants (Actual)InterventionalCompleted
Open-label, Randomized, Single-dose, 2-way Crossover Study to Investigate Safety and Pharmacokinetics of Mitiglinide and Metformin in Free Combination and Fixed-dose Combination in Healthy Male Subjects. [NCT01443221]Phase 124 participants (Actual)Interventional2010-12-31Completed
A Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10 mg (Mitiglinide) in Type 2 Diabetes Mellitus Patients With Normal or Moderate Impaired Hepatic Function [NCT04349696]Phase 416 participants (Actual)Interventional2014-02-11Completed
What is the Effects of Incretin on the Blood Pressure and Lipid in Overweight or Obese Diabetes Patients With Masked Hypertension: Liraglutide Plus Mitiglinide Comparing Metformin Plus Mitiglinide or Mitiglinide Alone(BLOOD STUDY) [NCT02503943]Phase 490 participants (Anticipated)Interventional2015-05-31Active, not recruiting
[NCT02154347]Phase 4178 participants (Actual)InterventionalCompleted
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01333592 (2) [back to overview]Change From Baseline in HbA1c at 52 Weeks
NCT01333592 (2) [back to overview]Incidences of Adverse Events
NCT02154347 (1) [back to overview]Change From Baseline in HbA1c

Change From Baseline in HbA1c at 52 Weeks

(NCT01333592)
Timeframe: at week 0 and week 52

Interventionpercentage of HbA1c (Mean)
KAD-1229 / DPP-4 Inhibitors-0.45
KAD-1229 / Biguanides-0.28

[back to top]

Incidences of Adverse Events

(NCT01333592)
Timeframe: 52 weeks

InterventionParticipants (Number)
KAD-1229 / DPP-4 Inhibitors48
KAD-1229 / Biguanides57

[back to top]

Change From Baseline in HbA1c

(NCT02154347)
Timeframe: 16 weeks

Intervention% (value of HbA1c) (Mean)
Placebo/KAD-12290.05
KAD-1229/KAD-1229-0.61

[back to top]